Study results presented at 2018 ASCO Annual Meeting demonstrated effectiveness of ado-trastuzumab emtansine in non-breast non-gastric HER2-amplified cancers.
Study results support the role of androgens and benefits of 5-alpha-reductase inhibition in the progression of bladder cancer.
Enfortumab vedotin was granted Breakthrough Therapy Designation by the US Food and Drug Administration (FDA), based on interim results from a Phase 1 study.
Recent research shows that although testicular cancer survivors do not totally conform to the criteria for metabolic syndrome, past treatment with platinum-based chemotherapy increases its prevalence among survivors and may lead to a greater risk for heart disease in this patient population.
Results from the ongoing Platinum Study revealed the prevalence of risk factors for CVD among survivors of testicular cancer who received chemotherapy for their cancer.
Patients on hemodialysis that underwent radical cystectomy for bladder cancer experienced increased mortality.
After assessing and addressing nurse knowledge of use of the Confusion Assessment Method (CAM) tool, implementation of screening protocol improved interventions for older hospitalized patients who had undergone urological surgery. These results were presented in a poster at the NACNS 2018 Annual Conference.
Phase 3 study sought to assess the associations between adjuvant therapy with VEGF-tyrosine kinase inhibitors (TKIs) and benefit, sex, and age in patients with resected renal cell cancer.
Investigators compared adjuvant gemcitabine plus cisplatin vs surveillance and subsequent chemotherapy if needed for patients who underwent nephron-ureterectomy for UTUC.
Researchers evaluated the effect of antibiotics on treatment delays, interruptions, and dose reductions in patients with mRCC treated with a first-line VEGF-TKI and presented their results at the 2018 Genitourinary Cancers Symposium.
In the IMvigor 311 trial, researchers sought to determine if atezolizumab improves overall survival for patients with metastatic urothelial carcinoma vs physicians' choice of 3 IV regimens.
A feasibility study involving 60 patients with bladder cancer sought to determine if preoperative vigorous cardiovascular activity would improve postsurgical outcomes.
Using a data sample from the CDC National Program for Cancer Registries, investigators determined how demographic factors — age, race, and sex — impact 5-year survival rates for HPV-associated cancers from initial diagnosis until death.
Approximately 50% of patients with advanced urothelial carcinoma are unable to receive standard first-line cisplatin-based chemotherapy, indicating a need for additional treatment options.
Flushing the bladder with a chemotherapeutic agent after tumor resection significantly reduced recurrence rates of bladder cancer.
Studies presented in the last year demonstrated a revolutionary role for immune checkpoint inhibitors in the treatment of urothelial carcinoma.
Adding chemotherapy with fluorouracil and mitomycin to radiotherapy improves locoregional control.
Survivors of testicular cancer are more likely to develop metabolic syndrome after platinum-based chemotherapy.
The US Food and Drug Administration has approved nivolumab (Opdivo) for the treatment of patients with locally advanced or metastatic bladder cancer.
Faced with a harsh treatment option, a patient with genitourinary cancer helps create a treatment plan that preserves his self-image.
Single-agent nivolumab induced durable clinical responses with a manageable safety profile in previously treated patients with locally advanced or metastatic urothelial carcinoma.
Emulsifying Mycobacterium brumae in olive oil appeared promising for producing a robust immune response in preclinical tests. Recent research has indicated that M brumae is a safer alternative to BCG.
Researchers in Sweden have, for the first time, estimated the risk of developing various types of prostate cancer for men with brothers and/or fathers with the disease.
Functional status, a person's ability to perform normal activities of daily living, is associated with treatment choice for patients with prostate cancer.
Although overall risk for uterine cancer after risk-reducing salpingo-oophorectomy is not increased, the risk of serous/serous-like endometrial carcinoma is higher for BRCA1+ women.
US FDA granted accelerated approval to atezolizumab (TECENTRIQ), indicated for the treatment of locally advanced or metastatic UC in patients whose disease progressed during or following platinum-based chemotherapy, or in the neoadjuvant or adjuvant setting.
Although HPV vaccination is expected to decrease the cancer burden from HPV across all racial and ethnic groups, some disparities are expected to persist and widen if their causes are not addressed, including lack of access to screening, timely diagnoses, and treatment.
Patients with stage IIA testicular cancer gain a survival advantage from treatment with radiation therapy compared with chemotherapy.
Researchers believe arsenic exposure might contribute to higher-than-normal rates of bladder cancer in the region.
Pioglitazone use correlated with increased rates of bladder cancer across a large population. The risk of developing bladder cancer also increased with higher dose and longer use of the drug.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
- Drug Classification of Trastuzumab
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|